XORTX Therapeutics Inc. (XRTX)

2.9600 -0.1100 (-3.58%) As of 12:57PM EDT. Market open.

XORTX Therapeutics Inc.

3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
403 455 7727
https://www.xortx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Allen Warren Davidoff Ph.D.	Founder, CEO, President & Director	356.04k	N/A	1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D	Interim Chief Financial Officer	42.47k	N/A	1963
Dr. Stephen Haworth M.D., MRCP	Chief Medical Officer	226.83k	N/A	1950
Dr. Stacy Evans M.B.A., M.D.	Chief Business Officer	83.96k	N/A	1974
Nick Rigopoulos	Director of Communications	N/A	N/A	N/A
Dr. David Sans M.B.A., Ph.D.	Director of Corporate Development	N/A	N/A	1970
Dr. David MacDonald Ph.D.	Consultant of Clinical Operations	N/A	N/A	1964
Ms. Charlotte May	Corporate Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.

Corporate governance

XORTX Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.